Patient-reported outcome (PRO)-based symptom assessment in patients with advanced lung cancer receiving first-line combination immunotherapy: a protocol for a multicenter, prospective, observational study

Yuanle Deng,Han Hu,Rong Jia,Wei Dai,Dengfeng Wang,Purong Zhang,Peng Zhang,Kai Cheng,Jianning Tang,Yan Wen,Xiang Zhou,Qiuling Shi,Zhujuan Xiong,Jin Zhou
DOI: https://doi.org/10.1186/s12890-023-02432-5
IF: 3.1
2023-05-20
BMC Pulmonary Medicine
Abstract:Immunotherapy is currently applied in the first-line treatment regimens for numerous advanced cancers, especially advanced lung cancer. Immune-related adverse events (irAEs) resulting from immunotherapy can vary in severity and cause a substantial symptom burden to patients. However, there are limited data on symptom burden in patients with advanced lung cancer following immunotherapy. To address this deficit, this study aims to provide insight into the symptom burden and severity through patient-reported outcome measurements and conduct an analysis of temporal trends and clinical consequences of symptom burden in patients with advanced lung cancer receiving combination immunotherapy.
respiratory system
What problem does this paper attempt to address?